Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Stevens

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Chemical Research in Toxicology|September 16, 2003
An evaluation of a low-density DNA microarray using cytochrome P450 inducersGeorgina Meneses-Lorente, Françoise de Longueville, Sofia Dos Santos-Mendes, et al.
Biopharmaceutics & Drug Disposition|June 16, 2007
Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligandsAndrew Pike, Susan M Cook, Alan P Watt, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 14, 2006
Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomographyJohn R Atack, Paul Scott-Stevens, John S Beech, et al.
Heart Rhythm|August 12, 2014
Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementiaVictoria Jacobs, Scott C Woller, Scott Stevens, et al.
Plos One|March 20, 2015
First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled studyNiels Andreasen, Monica Simeoni, Henrik Ostlund, et al.
Journal of Medicinal Chemistry|August 25, 2021
Optimization of a Series of RIPK2 PROTACsAfjal H Miah, Ian E D Smith, Mark Rackham, et al.
Angewandte Chemie (International Ed. in English)|August 20, 2021
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACsRobert P Law, Joao Nunes, Chun-Wa Chung, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 26, 2009
Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humansJohn R Atack, Dean F Wong, Tim D Fryer, et al.
Journal of Medicinal Chemistry|January 29, 2019
Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS MethodologiesGraham L Simpson, Sophie M Bertrand, Jennifer A Borthwick, et al.
Communications Biology|March 22, 2020
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2Alina Mares, Afjal H Miah, Ian E D Smith, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Chemical Research in Toxicology|September 16, 2003
An evaluation of a low-density DNA microarray using cytochrome P450 inducersGeorgina Meneses-Lorente, Françoise de Longueville, Sofia Dos Santos-Mendes, et al.
Biopharmaceutics & Drug Disposition|June 16, 2007
Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligandsAndrew Pike, Susan M Cook, Alan P Watt, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 14, 2006
Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] occupancy of rat brain gamma-aminobutyric acid(A) receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission tomographyJohn R Atack, Paul Scott-Stevens, John S Beech, et al.
Heart Rhythm|August 12, 2014
Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementiaVictoria Jacobs, Scott C Woller, Scott Stevens, et al.
Plos One|March 20, 2015
First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled studyNiels Andreasen, Monica Simeoni, Henrik Ostlund, et al.
Journal of Medicinal Chemistry|August 25, 2021
Optimization of a Series of RIPK2 PROTACsAfjal H Miah, Ian E D Smith, Mark Rackham, et al.
Angewandte Chemie (International Ed. in English)|August 20, 2021
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACsRobert P Law, Joao Nunes, Chun-Wa Chung, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 26, 2009
Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humansJohn R Atack, Dean F Wong, Tim D Fryer, et al.
Journal of Medicinal Chemistry|January 29, 2019
Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS MethodologiesGraham L Simpson, Sophie M Bertrand, Jennifer A Borthwick, et al.
Communications Biology|March 22, 2020
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2Alina Mares, Afjal H Miah, Ian E D Smith, et al.
Pageof 6